1. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner
- Author
-
Elodie Belnoue, Floriane Auderset, Paul-Henri Lambert, Claire-Anne Siegrist, and Beatris Mastelic-Gavillet
- Subjects
0301 basic medicine ,follicular T helper cells ,Signal Transduction / immunology ,Th1 Cells / immunology ,Receptor, Interferon alpha-beta ,ddc:616.07 ,Receptor, Interferon alpha-beta / genetics ,Ligands ,B-Lymphocytes / immunology ,Monocytes ,NF-kappa B / immunology ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,germinal centers ,Immunology and Allergy ,Cationic liposome ,Receptor ,Original Research ,Mice, Knockout ,B-Lymphocytes ,ddc:618 ,Membrane Glycoproteins ,TLR7/8 agonist ,NF-kappa B ,T helper cell ,Cell biology ,Liposome ,medicine.anatomical_structure ,Interferon Type I ,liposome ,Phosphatidylcholines ,Germinal centers ,Adjuvants, Immunologic / administration & dosage ,Follicular T helper cells ,Heterocyclic Compounds, 3-Ring ,Stearic Acids ,Signal Transduction ,lcsh:Immunologic diseases. Allergy ,Liposomes / administration & dosage ,Stearic Acids / administration & dosage ,Interferon Type I / immunology ,Drug Compounding ,NF-kappa B / deficiency ,Immunology ,Membrane Glycoproteins / agonists ,Phosphatidylcholines / administration & dosage ,Toll-Like Receptor 7 / agonists ,03 medical and health sciences ,Adjuvants, Immunologic ,Immunity ,Adjuvanticity ,medicine ,Dendritic Cells / immunology ,Animals ,adjuvants for vaccine ,Receptor, Interferon alpha-beta / immunology ,Adjuvants for vaccine ,Heterocyclic Compounds, 3-Ring / administration & dosage ,Toll-Like Receptor 8 / agonists ,Germinal center ,NF-κB ,TLR7 ,Dendritic Cells ,Th1 Cells ,Monocytes / immunology ,Germinal Center ,Immunity, Innate ,NF-kappa B / genetics ,Mice, Inbred C57BL ,Germinal Center / immunology ,030104 developmental biology ,Receptor, Interferon alpha-beta / deficiency ,chemistry ,Toll-Like Receptor 7 ,Toll-Like Receptor 8 ,Liposomes ,lcsh:RC581-607 ,030215 immunology - Abstract
Novel adjuvants, such as Toll-like receptors (TLRs) agonists, are needed for the development of new formulations able to circumvent limitations of current vaccines. Among TLRs, TLR7/8 agonists represent promising candidates, as they are well described to enhance antigen-specific antibody responses and skew immunity toward T helper (TH) 1 responses. We find here that the incorporation of the synthetic TLR7/8 ligand 3M-052 in a cationic DOEPC-based liposome formulation shifts immunity toward TH1 responses and elicits strong and long-lasting germinal center and follicular T helper cell responses in adult mice. This reflects the prolonged recruitment of innate cells toward the site of immunization and homing of activated antigen-loaded monocytes and monocyte-derived dendritic cells toward draining lymph nodes. We further show that this adjuvanticity is independent of type I IFN but NF-κB-dependent. Overall, our data identify TLR7/8 agonists incorporated in liposomes as promising and effective adjuvants to enhance TH1 and germinal center responses.
- Published
- 2020
- Full Text
- View/download PDF